AffiliationDivision of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractDespite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
CitationLindsay CR, Blackhall FH. Direct Ras G12C inhibitors: crossing the rubicon. Br J Cancer. 2019;121(3):197-8.
JournalBritish Journal of Cancer
- Improving Prospects for Targeting RAS.
- Authors: Singh H, Longo DL, Chabner BA
- Issue date: 2015 Nov 1
- KRAS: From undruggable to a druggable Cancer Target.
- Authors: Uprety D, Adjei AA
- Issue date: 2020 Sep
- Inhibitors of K-Ras plasma membrane localization.
- Authors: Cho KJ, van der Hoeven D, Hancock JF
- Issue date: 2013
- RAS-targeted therapies: is the undruggable drugged?
- Authors: Moore AR, Rosenberg SC, McCormick F, Malek S
- Issue date: 2020 Aug
- Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
- Authors: Chen H, Smaill JB, Liu T, Ding K, Lu X
- Issue date: 2020 Dec 10